Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | SHBG | P04278 | 4/20 | 0.50 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 3/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7884266 | 1.00 | CYP19A1 (0.68) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL2600423 | 0.86 | CYP3A4 (0.69) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL11754343 | 0.86 | CYP3A4 (0.69) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL11754338 | 0.86 | CYP3A4 (0.69) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL2600417 | 0.84 | CYP19A1 (0.64) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL11425175 | 0.84 | CYP19A1 (0.64) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL2905967 | 0.83 | CYP19A1 (0.62) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL37618 | 0.83 | CYP3A4 (0.70) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL7884191 | 0.82 | CYP19A1 (0.61) | CYP19A1CYP3A4LMNASHBGSERPINA6 | |
| SCHEMBL9056946 | 0.82 | CYP19A1 (0.61) | CYP19A1CYP3A4LMNASHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | BERLINER DAVID L (US) | 2002-08-01 | — | — | US | disclosed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6066627-A | ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE | PHERIN CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057439-A | EPOXYSTEROIDS | PHERIN CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5969168-A | STIMULATE AUTONOMIC ACTIVITY | PHERIN CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | FABP7, NR3C2, NR3C1 | CYP19A1 109/4885CYP3A4 470/4885LMNA 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.